Investigating the effect of Ma-Al -Jabin on hyperactivity disorder

Effect of Ma-Al -Jabin on expression symptoms in hyperactivity disorder: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180303038930N1

Enrollment

Registered

2018-05-09

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperactivity in childhood with ADHD disorder. General psychiatric examination, not elsewhere classified

Interventions

Intervention 1: Intervention group: Receive a daily glass of traditional medicine MA AL JABIN. Intervention 2: Control group: Get a glass of placebo every day.

Eligibility

Sex/Gender

All

Age

6 Years to 13 Years

Inclusion criteria

Inclusion criteria: Children are between the ages of 13-6. Complete the consent form of the company in the study. Children with ADHD based on DSMV criteria.

Exclusion criteria

Exclusion criteria: History of other diseases, such as mental retardation, schizophrenia, insomnia, mood disorders, anxiety disorders and personality disorder due to drug or substance use

Design outcomes

Primary

Measure	Time frame
Hyper activity. Timepoint: effectiveness of whey protein(Maa-e-al Jobon)-Iranian Traditional medicine-on hyper activity in ADHDAt times before the study began and 4 weeks after the start of the study. Method of measurement: Patients are evaluated by two questionnaires of sdq-cpt.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Emtiazy

Yazd University of Medical Sciences

tebsonati@ssu.ac.ir+98 35 3723 8915

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026